Todd Hankinson
Concepts (456)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Craniopharyngioma | 21 | 2025 | 74 | 7.400 |
Why?
| | Pituitary Neoplasms | 18 | 2025 | 190 | 5.410 |
Why?
| | Hydrocephalus | 17 | 2025 | 106 | 3.610 |
Why?
| | Brain Neoplasms | 29 | 2025 | 1241 | 3.540 |
Why?
| | Arnold-Chiari Malformation | 13 | 2025 | 27 | 3.520 |
Why?
| | Neurosurgical Procedures | 14 | 2024 | 199 | 3.330 |
Why?
| | Brain Stem Neoplasms | 5 | 2016 | 83 | 1.820 |
Why?
| | Ganglioglioma | 5 | 2025 | 35 | 1.760 |
Why?
| | Atlanto-Axial Joint | 7 | 2020 | 13 | 1.640 |
Why?
| | Ependymoma | 11 | 2025 | 168 | 1.600 |
Why?
| | Joint Instability | 7 | 2020 | 170 | 1.580 |
Why?
| | Glioma | 7 | 2025 | 397 | 1.580 |
Why?
| | Child | 89 | 2025 | 22037 | 1.550 |
Why?
| | Ventriculoperitoneal Shunt | 10 | 2025 | 36 | 1.550 |
Why?
| | Magnetic Resonance Imaging | 21 | 2023 | 3722 | 1.540 |
Why?
| | Decompression, Surgical | 9 | 2024 | 100 | 1.500 |
Why?
| | Spinal Injuries | 4 | 2022 | 51 | 1.440 |
Why?
| | Cerebrospinal Fluid Shunts | 10 | 2025 | 30 | 1.420 |
Why?
| | Infratentorial Neoplasms | 8 | 2025 | 63 | 1.410 |
Why?
| | Spinal Fusion | 9 | 2024 | 251 | 1.330 |
Why?
| | Pons | 4 | 2016 | 27 | 1.170 |
Why?
| | Child, Preschool | 45 | 2025 | 11097 | 1.150 |
Why?
| | Occipital Bone | 5 | 2024 | 18 | 1.140 |
Why?
| | Cervical Atlas | 3 | 2024 | 4 | 1.110 |
Why?
| | Sella Turcica | 2 | 2017 | 18 | 1.100 |
Why?
| | Xanthomatosis | 2 | 2017 | 9 | 1.090 |
Why?
| | Cervical Vertebrae | 9 | 2025 | 135 | 1.070 |
Why?
| | Dura Mater | 3 | 2021 | 32 | 1.050 |
Why?
| | Syringomyelia | 5 | 2024 | 10 | 0.990 |
Why?
| | Tomography, X-Ray Computed | 11 | 2022 | 2681 | 0.970 |
Why?
| | Humans | 133 | 2025 | 137514 | 0.940 |
Why?
| | Infant | 34 | 2025 | 9467 | 0.910 |
Why?
| | Hematoma, Epidural, Spinal | 1 | 2023 | 4 | 0.840 |
Why?
| | Machine Learning | 4 | 2025 | 496 | 0.840 |
Why?
| | Infant, Newborn | 17 | 2025 | 6059 | 0.790 |
Why?
| | Ventriculostomy | 7 | 2024 | 21 | 0.790 |
Why?
| | Neck Injuries | 1 | 2022 | 21 | 0.780 |
Why?
| | Neural Tube Defects | 4 | 2019 | 63 | 0.780 |
Why?
| | Cellular Senescence | 1 | 2024 | 188 | 0.770 |
Why?
| | Image Processing, Computer-Assisted | 2 | 2020 | 784 | 0.750 |
Why?
| | Adolescent | 46 | 2025 | 21555 | 0.750 |
Why?
| | Neuroprotection | 1 | 2022 | 42 | 0.740 |
Why?
| | Neurosurgery | 3 | 2013 | 39 | 0.730 |
Why?
| | SEER Program | 4 | 2018 | 218 | 0.720 |
Why?
| | Neuroendoscopy | 5 | 2024 | 23 | 0.690 |
Why?
| | Postoperative Complications | 13 | 2025 | 2641 | 0.690 |
Why?
| | Transcriptome | 8 | 2025 | 974 | 0.680 |
Why?
| | Male | 67 | 2025 | 67718 | 0.680 |
Why?
| | Diagnosis, Computer-Assisted | 1 | 2020 | 89 | 0.650 |
Why?
| | Down Syndrome | 2 | 2020 | 492 | 0.630 |
Why?
| | Reoperation | 6 | 2025 | 569 | 0.620 |
Why?
| | Female | 68 | 2025 | 73162 | 0.610 |
Why?
| | Atlanto-Occipital Joint | 3 | 2024 | 4 | 0.580 |
Why?
| | Retrospective Studies | 32 | 2025 | 15628 | 0.580 |
Why?
| | Neoplasm Recurrence, Local | 6 | 2024 | 1060 | 0.560 |
Why?
| | Treatment Outcome | 27 | 2024 | 10821 | 0.550 |
Why?
| | Infant, Premature | 1 | 2022 | 568 | 0.550 |
Why?
| | Pituitary Diseases | 1 | 2017 | 21 | 0.540 |
Why?
| | Third Ventricle | 4 | 2024 | 17 | 0.540 |
Why?
| | Axis, Cervical Vertebra | 2 | 2022 | 7 | 0.530 |
Why?
| | Central Nervous System Neoplasms | 2 | 2019 | 158 | 0.530 |
Why?
| | Meningioma | 1 | 2018 | 91 | 0.530 |
Why?
| | Meningeal Neoplasms | 1 | 2018 | 100 | 0.520 |
Why?
| | Intracranial Hemorrhages | 2 | 2020 | 84 | 0.510 |
Why?
| | Skull | 1 | 2017 | 139 | 0.500 |
Why?
| | Cerebral Ventricles | 2 | 2022 | 52 | 0.500 |
Why?
| | Supratentorial Neoplasms | 1 | 2015 | 17 | 0.490 |
Why?
| | Ketorolac | 1 | 2015 | 20 | 0.480 |
Why?
| | EGF Family of Proteins | 1 | 2015 | 16 | 0.480 |
Why?
| | Receptor, EphA2 | 1 | 2015 | 19 | 0.480 |
Why?
| | Lymphocyte Specific Protein Tyrosine Kinase p56(lck) | 1 | 2015 | 21 | 0.480 |
Why?
| | ErbB Receptors | 2 | 2016 | 616 | 0.470 |
Why?
| | Proto-Oncogene Proteins B-raf | 4 | 2025 | 227 | 0.470 |
Why?
| | Receptor, ErbB-3 | 1 | 2015 | 44 | 0.470 |
Why?
| | Temporal Lobe | 1 | 2015 | 91 | 0.470 |
Why?
| | Pediatrics | 2 | 2020 | 1123 | 0.460 |
Why?
| | Brain Injuries, Traumatic | 2 | 2019 | 358 | 0.460 |
Why?
| | Choroid Plexus Neoplasms | 1 | 2014 | 8 | 0.460 |
Why?
| | src-Family Kinases | 1 | 2015 | 94 | 0.450 |
Why?
| | Professional Practice | 1 | 2014 | 64 | 0.420 |
Why?
| | Perioperative Care | 1 | 2015 | 182 | 0.420 |
Why?
| | Data Collection | 2 | 2014 | 674 | 0.420 |
Why?
| | Spinal Cord Injuries | 3 | 2024 | 211 | 0.410 |
Why?
| | Delayed Diagnosis | 2 | 2024 | 91 | 0.410 |
Why?
| | Young Adult | 17 | 2021 | 13243 | 0.400 |
Why?
| | Scoliosis | 3 | 2024 | 216 | 0.400 |
Why?
| | Moyamoya Disease | 2 | 2014 | 20 | 0.400 |
Why?
| | Quality of Life | 5 | 2023 | 2870 | 0.390 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 1 | 2015 | 350 | 0.390 |
Why?
| | Neurology | 1 | 2014 | 114 | 0.390 |
Why?
| | Urethral Diseases | 1 | 2011 | 19 | 0.370 |
Why?
| | Drug Delivery Systems | 1 | 2015 | 363 | 0.370 |
Why?
| | Foreign-Body Migration | 1 | 2011 | 34 | 0.370 |
Why?
| | Decision Support Systems, Clinical | 2 | 2025 | 219 | 0.370 |
Why?
| | Artificial Intelligence | 2 | 2025 | 275 | 0.360 |
Why?
| | Genomics | 1 | 2016 | 793 | 0.360 |
Why?
| | Tumor Microenvironment | 4 | 2025 | 682 | 0.350 |
Why?
| | Intracranial Hypertension | 2 | 2010 | 38 | 0.350 |
Why?
| | Brain Injuries | 1 | 2016 | 493 | 0.350 |
Why?
| | Cranial Sutures | 1 | 2010 | 11 | 0.340 |
Why?
| | Odontoid Process | 1 | 2010 | 4 | 0.340 |
Why?
| | Cephalometry | 1 | 2010 | 34 | 0.340 |
Why?
| | Craniotomy | 2 | 2008 | 78 | 0.340 |
Why?
| | Esthetics | 1 | 2010 | 52 | 0.330 |
Why?
| | Internal Fixators | 1 | 2010 | 36 | 0.330 |
Why?
| | Spinal Diseases | 1 | 2010 | 48 | 0.320 |
Why?
| | Craniosynostoses | 1 | 2010 | 57 | 0.320 |
Why?
| | Gene Expression Regulation, Neoplastic | 5 | 2024 | 1402 | 0.320 |
Why?
| | Biomarkers, Tumor | 3 | 2024 | 1279 | 0.320 |
Why?
| | Surgeons | 1 | 2014 | 298 | 0.320 |
Why?
| | Societies, Medical | 1 | 2014 | 820 | 0.320 |
Why?
| | Urinary Bladder | 1 | 2011 | 185 | 0.320 |
Why?
| | Brain Stem | 1 | 2010 | 104 | 0.320 |
Why?
| | MAP Kinase Signaling System | 2 | 2024 | 322 | 0.310 |
Why?
| | Patient Discharge | 1 | 2016 | 895 | 0.310 |
Why?
| | Anemia, Sickle Cell | 2 | 2014 | 266 | 0.300 |
Why?
| | Glomus Tumor | 1 | 2008 | 2 | 0.300 |
Why?
| | Chromosomes, Human, Pair 1 | 2 | 2019 | 73 | 0.290 |
Why?
| | Neuroimaging | 3 | 2020 | 291 | 0.290 |
Why?
| | Orbital Neoplasms | 1 | 2008 | 24 | 0.290 |
Why?
| | Insurance, Liability | 1 | 2008 | 5 | 0.290 |
Why?
| | Cerebral Revascularization | 1 | 2008 | 19 | 0.290 |
Why?
| | RNA, Messenger | 2 | 2017 | 2838 | 0.290 |
Why?
| | Follow-Up Studies | 9 | 2024 | 5139 | 0.290 |
Why?
| | Brain | 5 | 2023 | 2831 | 0.280 |
Why?
| | Surgical Wound Infection | 3 | 2022 | 306 | 0.280 |
Why?
| | Medically Underserved Area | 1 | 2008 | 87 | 0.270 |
Why?
| | B7-H1 Antigen | 2 | 2020 | 218 | 0.270 |
Why?
| | Programmed Cell Death 1 Receptor | 2 | 2020 | 252 | 0.270 |
Why?
| | Adult | 19 | 2021 | 37821 | 0.260 |
Why?
| | Granuloma | 2 | 2017 | 91 | 0.260 |
Why?
| | Astrocytoma | 2 | 2025 | 128 | 0.260 |
Why?
| | Surgical Flaps | 1 | 2008 | 148 | 0.260 |
Why?
| | Evidence-Based Medicine | 1 | 2010 | 746 | 0.250 |
Why?
| | Clinical Decision-Making | 2 | 2019 | 321 | 0.250 |
Why?
| | Autophagy | 2 | 2019 | 282 | 0.240 |
Why?
| | Prognosis | 7 | 2019 | 4031 | 0.240 |
Why?
| | Subdural Effusion | 1 | 2024 | 3 | 0.230 |
Why?
| | Neocortex | 1 | 2025 | 39 | 0.230 |
Why?
| | Pyramidal Cells | 1 | 2025 | 75 | 0.230 |
Why?
| | Equipment Failure | 2 | 2025 | 108 | 0.230 |
Why?
| | Radiation Injuries | 2 | 2018 | 147 | 0.220 |
Why?
| | Radiographic Image Interpretation, Computer-Assisted | 1 | 2025 | 107 | 0.220 |
Why?
| | Computational Biology | 3 | 2025 | 645 | 0.220 |
Why?
| | Macrophage Activation | 1 | 2025 | 201 | 0.220 |
Why?
| | Adrenoleukodystrophy | 1 | 2024 | 9 | 0.220 |
Why?
| | Neuronavigation | 1 | 2024 | 7 | 0.220 |
Why?
| | Intraoperative Neurophysiological Monitoring | 1 | 2024 | 21 | 0.220 |
Why?
| | Clonal Evolution | 1 | 2024 | 45 | 0.220 |
Why?
| | Drainage | 1 | 2024 | 169 | 0.210 |
Why?
| | United States | 7 | 2020 | 14696 | 0.210 |
Why?
| | Microarray Analysis | 4 | 2017 | 116 | 0.210 |
Why?
| | Phagocytosis | 1 | 2025 | 379 | 0.210 |
Why?
| | Meningomyelocele | 2 | 2025 | 59 | 0.210 |
Why?
| | Tumor Burden | 1 | 2024 | 311 | 0.210 |
Why?
| | Attitude of Health Personnel | 1 | 2011 | 1169 | 0.200 |
Why?
| | Combined Modality Therapy | 3 | 2019 | 1241 | 0.200 |
Why?
| | Cohort Studies | 8 | 2024 | 5730 | 0.200 |
Why?
| | Brain Concussion | 2 | 2022 | 570 | 0.200 |
Why?
| | Germinoma | 1 | 2022 | 10 | 0.200 |
Why?
| | Pineal Gland | 1 | 2022 | 16 | 0.200 |
Why?
| | Pinealoma | 1 | 2022 | 10 | 0.200 |
Why?
| | Cysts | 1 | 2023 | 111 | 0.190 |
Why?
| | Nuclear Proteins | 2 | 2025 | 710 | 0.190 |
Why?
| | Hypothalamic Neoplasms | 1 | 2022 | 9 | 0.190 |
Why?
| | Hypothalamic Diseases | 1 | 2022 | 18 | 0.190 |
Why?
| | Hedgehog Proteins | 2 | 2022 | 197 | 0.190 |
Why?
| | Developing Countries | 1 | 2024 | 305 | 0.190 |
Why?
| | Software | 2 | 2025 | 670 | 0.190 |
Why?
| | Drug Screening Assays, Antitumor | 2 | 2021 | 196 | 0.180 |
Why?
| | Spine | 1 | 2023 | 174 | 0.180 |
Why?
| | Radiation | 1 | 2021 | 24 | 0.180 |
Why?
| | beta Catenin | 2 | 2024 | 251 | 0.180 |
Why?
| | Endoscopy | 2 | 2015 | 316 | 0.180 |
Why?
| | Chromosome Aberrations | 2 | 2023 | 157 | 0.180 |
Why?
| | Traction | 1 | 2021 | 20 | 0.180 |
Why?
| | Chromatin | 1 | 2025 | 524 | 0.180 |
Why?
| | Cerebral Hemorrhage | 1 | 2022 | 112 | 0.180 |
Why?
| | Neurosurgeons | 2 | 2019 | 19 | 0.180 |
Why?
| | Cell Line, Tumor | 5 | 2025 | 3420 | 0.180 |
Why?
| | Epilepsy | 1 | 2025 | 334 | 0.170 |
Why?
| | Cranial Fossa, Posterior | 1 | 2020 | 18 | 0.170 |
Why?
| | Kaplan-Meier Estimate | 4 | 2020 | 892 | 0.170 |
Why?
| | Disease Progression | 3 | 2024 | 2755 | 0.170 |
Why?
| | Delphi Technique | 4 | 2025 | 273 | 0.170 |
Why?
| | Preoperative Period | 1 | 2020 | 131 | 0.170 |
Why?
| | Tumor Suppressor Protein p53 | 1 | 2024 | 531 | 0.170 |
Why?
| | Cerebellar Neoplasms | 1 | 2022 | 155 | 0.160 |
Why?
| | Neoplasms, Neuroepithelial | 1 | 2019 | 17 | 0.160 |
Why?
| | Neoplastic Cells, Circulating | 1 | 2020 | 80 | 0.160 |
Why?
| | Databases, Factual | 2 | 2016 | 1351 | 0.160 |
Why?
| | Medulloblastoma | 1 | 2022 | 196 | 0.160 |
Why?
| | Prophylactic Surgical Procedures | 1 | 2019 | 7 | 0.160 |
Why?
| | Benchmarking | 1 | 2021 | 184 | 0.160 |
Why?
| | Sports | 1 | 2022 | 229 | 0.160 |
Why?
| | Adenomatous Polyposis Coli | 1 | 2019 | 34 | 0.160 |
Why?
| | Middle Aged | 12 | 2020 | 33355 | 0.160 |
Why?
| | Spinal Cord Diseases | 1 | 2019 | 42 | 0.160 |
Why?
| | Optic Nerve Neoplasms | 1 | 2019 | 11 | 0.160 |
Why?
| | Optic Chiasm | 1 | 2019 | 18 | 0.160 |
Why?
| | Gene Expression Profiling | 4 | 2020 | 1770 | 0.150 |
Why?
| | Intracranial Pressure | 1 | 2019 | 47 | 0.150 |
Why?
| | Hematoma, Subdural | 1 | 2018 | 18 | 0.150 |
Why?
| | Neoplasm Grading | 2 | 2021 | 308 | 0.150 |
Why?
| | Multivariate Analysis | 3 | 2020 | 1524 | 0.150 |
Why?
| | Cerebellum | 1 | 2020 | 225 | 0.150 |
Why?
| | Decompressive Craniectomy | 1 | 2018 | 8 | 0.150 |
Why?
| | Craniospinal Irradiation | 1 | 2018 | 5 | 0.150 |
Why?
| | Spinal Curvatures | 1 | 2018 | 4 | 0.150 |
Why?
| | Specialties, Surgical | 1 | 2019 | 74 | 0.150 |
Why?
| | Healthcare Disparities | 1 | 2025 | 651 | 0.150 |
Why?
| | Chemoradiotherapy | 1 | 2019 | 226 | 0.140 |
Why?
| | Stromal Cells | 1 | 2018 | 111 | 0.140 |
Why?
| | Skull Neoplasms | 1 | 2017 | 23 | 0.140 |
Why?
| | Phenotype | 2 | 2024 | 3205 | 0.140 |
Why?
| | Bone Transplantation | 1 | 2018 | 95 | 0.140 |
Why?
| | Risk Factors | 7 | 2022 | 10356 | 0.140 |
Why?
| | Bone Resorption | 1 | 2018 | 86 | 0.140 |
Why?
| | Cyst Fluid | 1 | 2017 | 25 | 0.140 |
Why?
| | Oncogene Proteins, Fusion | 1 | 2019 | 215 | 0.140 |
Why?
| | Macrophages | 1 | 2025 | 1548 | 0.140 |
Why?
| | Hypophysitis | 1 | 2017 | 3 | 0.140 |
Why?
| | Single-Cell Analysis | 1 | 2020 | 309 | 0.140 |
Why?
| | Fetus | 1 | 2022 | 807 | 0.140 |
Why?
| | Re-Irradiation | 1 | 2016 | 8 | 0.130 |
Why?
| | Patient Admission | 1 | 2018 | 191 | 0.130 |
Why?
| | Chloroquine | 1 | 2017 | 52 | 0.130 |
Why?
| | Models, Theoretical | 1 | 2020 | 576 | 0.130 |
Why?
| | Survival Analysis | 2 | 2023 | 1320 | 0.130 |
Why?
| | Aged, 80 and over | 4 | 2018 | 7593 | 0.130 |
Why?
| | Blood Transfusion | 1 | 2019 | 324 | 0.130 |
Why?
| | Nurses | 1 | 2019 | 174 | 0.130 |
Why?
| | Sarcoma, Ewing | 1 | 2017 | 95 | 0.130 |
Why?
| | Algorithms | 2 | 2022 | 1702 | 0.130 |
Why?
| | Glioblastoma | 2 | 2010 | 344 | 0.130 |
Why?
| | Observer Variation | 1 | 2017 | 347 | 0.130 |
Why?
| | Aged | 7 | 2019 | 23798 | 0.130 |
Why?
| | Organ Size | 1 | 2017 | 479 | 0.130 |
Why?
| | Antineoplastic Agents | 2 | 2018 | 2145 | 0.130 |
Why?
| | Age Factors | 3 | 2020 | 3301 | 0.120 |
Why?
| | Accidents, Traffic | 2 | 2014 | 189 | 0.120 |
Why?
| | Athletic Injuries | 1 | 2022 | 525 | 0.120 |
Why?
| | Cetirizine | 1 | 2015 | 2 | 0.120 |
Why?
| | Ambrosia | 1 | 2015 | 7 | 0.120 |
Why?
| | Nasal Sprays | 1 | 2015 | 5 | 0.120 |
Why?
| | Consensus | 3 | 2025 | 685 | 0.120 |
Why?
| | Amphiregulin | 1 | 2015 | 25 | 0.120 |
Why?
| | Cataract | 1 | 2018 | 213 | 0.120 |
Why?
| | Rhinitis, Allergic, Seasonal | 1 | 2015 | 29 | 0.120 |
Why?
| | Fluticasone | 1 | 2015 | 90 | 0.120 |
Why?
| | Length of Stay | 2 | 2019 | 1210 | 0.110 |
Why?
| | Cytokines | 3 | 2018 | 2095 | 0.110 |
Why?
| | Radiography | 4 | 2023 | 834 | 0.110 |
Why?
| | Cerebral Veins | 1 | 2014 | 16 | 0.110 |
Why?
| | Logistic Models | 3 | 2019 | 2064 | 0.110 |
Why?
| | Mice | 7 | 2025 | 17843 | 0.100 |
Why?
| | Indoles | 1 | 2017 | 415 | 0.100 |
Why?
| | Chromosomes | 2 | 2024 | 108 | 0.100 |
Why?
| | Mutation | 5 | 2025 | 3964 | 0.100 |
Why?
| | Disease-Free Survival | 1 | 2015 | 690 | 0.100 |
Why?
| | Arachnoid Cysts | 1 | 2013 | 7 | 0.100 |
Why?
| | Central Nervous System Cysts | 1 | 2013 | 14 | 0.100 |
Why?
| | Sulfonamides | 1 | 2017 | 513 | 0.100 |
Why?
| | Survival Rate | 2 | 2019 | 1980 | 0.100 |
Why?
| | Neuroectodermal Tumors, Primitive | 1 | 2012 | 11 | 0.100 |
Why?
| | Neuropsychological Tests | 2 | 2023 | 1066 | 0.100 |
Why?
| | Carcinoma | 1 | 2014 | 237 | 0.100 |
Why?
| | Seasons | 1 | 2015 | 546 | 0.100 |
Why?
| | Cerebral Angiography | 2 | 2014 | 109 | 0.100 |
Why?
| | Imaging, Three-Dimensional | 3 | 2017 | 581 | 0.100 |
Why?
| | Up-Regulation | 1 | 2015 | 846 | 0.100 |
Why?
| | Disease Models, Animal | 2 | 2019 | 4295 | 0.090 |
Why?
| | Ischemic Attack, Transient | 2 | 2014 | 66 | 0.090 |
Why?
| | Emergency Service, Hospital | 1 | 2023 | 2054 | 0.090 |
Why?
| | Drug Resistance, Neoplasm | 1 | 2017 | 806 | 0.090 |
Why?
| | Anti-Bacterial Agents | 1 | 2022 | 1800 | 0.090 |
Why?
| | Proportional Hazards Models | 1 | 2015 | 1263 | 0.090 |
Why?
| | Urethra | 1 | 2011 | 55 | 0.090 |
Why?
| | Registries | 3 | 2025 | 2021 | 0.090 |
Why?
| | Lymphangioma, Cystic | 1 | 2011 | 5 | 0.090 |
Why?
| | Neoplasms, Multiple Primary | 1 | 2011 | 57 | 0.090 |
Why?
| | Umbilicus | 1 | 2011 | 18 | 0.090 |
Why?
| | Neurologic Examination | 1 | 2011 | 113 | 0.090 |
Why?
| | Tumor Cells, Cultured | 2 | 2025 | 957 | 0.090 |
Why?
| | Brachial Plexus | 1 | 2011 | 30 | 0.090 |
Why?
| | Signal Transduction | 2 | 2025 | 5096 | 0.090 |
Why?
| | Hematoma, Epidural, Cranial | 1 | 2010 | 6 | 0.090 |
Why?
| | Teratoma | 1 | 2011 | 114 | 0.090 |
Why?
| | Magnetic Resonance Angiography | 2 | 2014 | 240 | 0.080 |
Why?
| | Rhabdoid Tumor | 1 | 2011 | 99 | 0.080 |
Why?
| | Radiosurgery | 1 | 2014 | 346 | 0.080 |
Why?
| | Gene Expression | 1 | 2015 | 1505 | 0.080 |
Why?
| | Practice Patterns, Physicians' | 1 | 2018 | 1312 | 0.080 |
Why?
| | Cell Proliferation | 3 | 2025 | 2482 | 0.080 |
Why?
| | Skull Fracture, Depressed | 1 | 2008 | 1 | 0.080 |
Why?
| | Reproducibility of Results | 1 | 2017 | 3292 | 0.080 |
Why?
| | Head Injuries, Closed | 1 | 2008 | 48 | 0.070 |
Why?
| | Animals | 7 | 2025 | 37011 | 0.070 |
Why?
| | Zygoma | 1 | 2008 | 8 | 0.070 |
Why?
| | Pia Mater | 1 | 2008 | 6 | 0.070 |
Why?
| | Computer Simulation | 3 | 2021 | 986 | 0.070 |
Why?
| | Functional Laterality | 1 | 2009 | 229 | 0.070 |
Why?
| | Electronic Health Records | 1 | 2016 | 1040 | 0.070 |
Why?
| | Topography, Medical | 1 | 2008 | 11 | 0.070 |
Why?
| | Diagnosis, Differential | 2 | 2012 | 1486 | 0.070 |
Why?
| | Temporal Arteries | 1 | 2008 | 45 | 0.070 |
Why?
| | Biopsy | 1 | 2011 | 1132 | 0.070 |
Why?
| | Models, Anatomic | 1 | 2008 | 98 | 0.070 |
Why?
| | Foreign Bodies | 1 | 2008 | 104 | 0.070 |
Why?
| | Developmental Disabilities | 1 | 2010 | 266 | 0.070 |
Why?
| | Abnormalities, Multiple | 1 | 2009 | 189 | 0.070 |
Why?
| | Prenatal Diagnosis | 1 | 2009 | 202 | 0.070 |
Why?
| | Paraganglioma | 1 | 2008 | 51 | 0.070 |
Why?
| | Diagnostic Imaging | 1 | 2010 | 339 | 0.070 |
Why?
| | Population Dynamics | 1 | 2008 | 149 | 0.070 |
Why?
| | Recurrence | 1 | 2010 | 1060 | 0.070 |
Why?
| | Cognition Disorders | 1 | 2010 | 517 | 0.060 |
Why?
| | Health Services Needs and Demand | 1 | 2008 | 270 | 0.060 |
Why?
| | Forecasting | 1 | 2008 | 386 | 0.060 |
Why?
| | Cerebrovascular Circulation | 1 | 2008 | 242 | 0.060 |
Why?
| | Gestational Age | 1 | 2009 | 903 | 0.060 |
Why?
| | CD47 Antigen | 1 | 2025 | 38 | 0.060 |
Why?
| | Malformations of Cortical Development | 1 | 2025 | 13 | 0.060 |
Why?
| | Head and Neck Neoplasms | 1 | 2011 | 617 | 0.060 |
Why?
| | Cranial Fontanelles | 1 | 2024 | 3 | 0.060 |
Why?
| | Cell Survival | 2 | 2019 | 1122 | 0.060 |
Why?
| | Seizures | 1 | 2008 | 431 | 0.060 |
Why?
| | Glasgow Coma Scale | 2 | 2018 | 182 | 0.060 |
Why?
| | X-ray Repair Cross Complementing Protein 1 | 1 | 2023 | 13 | 0.050 |
Why?
| | Radiotherapy, Adjuvant | 1 | 2024 | 218 | 0.050 |
Why?
| | Intelligence Tests | 1 | 2023 | 59 | 0.050 |
Why?
| | Stroke | 2 | 2014 | 1129 | 0.050 |
Why?
| | Isocitrate Dehydrogenase | 1 | 2024 | 60 | 0.050 |
Why?
| | Heart Atria | 1 | 2024 | 136 | 0.050 |
Why?
| | Drug Resistant Epilepsy | 1 | 2025 | 102 | 0.050 |
Why?
| | Cranial Irradiation | 1 | 2023 | 69 | 0.050 |
Why?
| | Fluorouracil | 1 | 2024 | 213 | 0.050 |
Why?
| | Sex Factors | 1 | 2009 | 2074 | 0.050 |
Why?
| | Patients' Rooms | 1 | 2022 | 12 | 0.050 |
Why?
| | Prospective Studies | 3 | 2024 | 7598 | 0.050 |
Why?
| | Abdomen | 1 | 2023 | 125 | 0.050 |
Why?
| | Narcotics | 1 | 2022 | 52 | 0.050 |
Why?
| | Action Potentials | 1 | 2025 | 502 | 0.050 |
Why?
| | Catheters | 1 | 2022 | 72 | 0.050 |
Why?
| | Gene Ontology | 1 | 2021 | 53 | 0.050 |
Why?
| | Multicenter Studies as Topic | 1 | 2023 | 308 | 0.050 |
Why?
| | Mass Screening | 1 | 2010 | 1264 | 0.050 |
Why?
| | NF-kappa B | 1 | 2025 | 694 | 0.050 |
Why?
| | Vancomycin | 1 | 2022 | 84 | 0.040 |
Why?
| | Slit Ventricle Syndrome | 1 | 2020 | 1 | 0.040 |
Why?
| | Epithelial-Mesenchymal Transition | 1 | 2023 | 212 | 0.040 |
Why?
| | Transplants | 1 | 2021 | 36 | 0.040 |
Why?
| | Postoperative Care | 1 | 2022 | 258 | 0.040 |
Why?
| | Transplantation, Heterologous | 1 | 2021 | 195 | 0.040 |
Why?
| | DNA Copy Number Variations | 1 | 2021 | 185 | 0.040 |
Why?
| | Models, Biological | 1 | 2008 | 1775 | 0.040 |
Why?
| | Transplantation, Autologous | 1 | 2021 | 238 | 0.040 |
Why?
| | Survivors | 1 | 2023 | 489 | 0.040 |
Why?
| | Recovery of Function | 1 | 2024 | 662 | 0.040 |
Why?
| | Genes, APC | 1 | 2019 | 12 | 0.040 |
Why?
| | Aminopyridines | 1 | 2019 | 101 | 0.040 |
Why?
| | Mice, SCID | 1 | 2019 | 367 | 0.040 |
Why?
| | Asymptomatic Diseases | 1 | 2019 | 87 | 0.040 |
Why?
| | Athletes | 1 | 2022 | 406 | 0.040 |
Why?
| | Critical Care Nursing | 1 | 2019 | 37 | 0.040 |
Why?
| | Blood Loss, Surgical | 1 | 2019 | 101 | 0.040 |
Why?
| | Benzamides | 1 | 2019 | 218 | 0.040 |
Why?
| | Surgical Wound | 1 | 2018 | 22 | 0.040 |
Why?
| | Electronic Mail | 1 | 2018 | 61 | 0.040 |
Why?
| | Odontogenesis | 1 | 2018 | 11 | 0.040 |
Why?
| | Point Mutation | 1 | 2019 | 234 | 0.040 |
Why?
| | Germ-Line Mutation | 1 | 2019 | 172 | 0.040 |
Why?
| | Immunohistochemistry | 2 | 2013 | 1740 | 0.040 |
Why?
| | Weight Gain | 1 | 2022 | 518 | 0.040 |
Why?
| | Laser Capture Microdissection | 1 | 2018 | 33 | 0.040 |
Why?
| | Longitudinal Studies | 2 | 2018 | 2857 | 0.040 |
Why?
| | Standard of Care | 1 | 2018 | 74 | 0.040 |
Why?
| | Tissue Culture Techniques | 1 | 2018 | 77 | 0.040 |
Why?
| | Mice, Inbred NOD | 1 | 2019 | 601 | 0.040 |
Why?
| | Drug Approval | 1 | 2018 | 87 | 0.040 |
Why?
| | Receptors, HIV | 1 | 2017 | 24 | 0.030 |
Why?
| | Mucin-1 | 1 | 2017 | 21 | 0.030 |
Why?
| | Cytogenetic Analysis | 1 | 2017 | 34 | 0.030 |
Why?
| | Receptors, Interleukin-6 | 1 | 2017 | 43 | 0.030 |
Why?
| | Fluorescent Antibody Technique | 1 | 2018 | 386 | 0.030 |
Why?
| | Pituitary Gland | 1 | 2018 | 149 | 0.030 |
Why?
| | Indoleamine-Pyrrole 2,3,-Dioxygenase | 1 | 2017 | 56 | 0.030 |
Why?
| | Monitoring, Physiologic | 1 | 2019 | 267 | 0.030 |
Why?
| | Heart-Assist Devices | 1 | 2003 | 550 | 0.030 |
Why?
| | Canada | 1 | 2018 | 421 | 0.030 |
Why?
| | Overweight | 1 | 2022 | 554 | 0.030 |
Why?
| | DNA-Binding Proteins | 2 | 2017 | 1507 | 0.030 |
Why?
| | Treatment Failure | 1 | 2018 | 353 | 0.030 |
Why?
| | Ki-67 Antigen | 1 | 2017 | 112 | 0.030 |
Why?
| | Brain Diseases | 1 | 2018 | 141 | 0.030 |
Why?
| | Prevalence | 2 | 2016 | 2719 | 0.030 |
Why?
| | Glial Fibrillary Acidic Protein | 1 | 2017 | 100 | 0.030 |
Why?
| | Heart Transplantation | 1 | 2003 | 749 | 0.030 |
Why?
| | Neuroglia | 1 | 2018 | 172 | 0.030 |
Why?
| | Blotting, Western | 1 | 2019 | 1227 | 0.030 |
Why?
| | Xenograft Model Antitumor Assays | 1 | 2019 | 868 | 0.030 |
Why?
| | Wounds, Nonpenetrating | 1 | 2019 | 275 | 0.030 |
Why?
| | Health Surveys | 1 | 2018 | 520 | 0.030 |
Why?
| | Transcription Factors | 2 | 2017 | 1717 | 0.030 |
Why?
| | Intensive Care Units, Pediatric | 1 | 2018 | 233 | 0.030 |
Why?
| | DNA Methylation | 1 | 2021 | 644 | 0.030 |
Why?
| | Pregnancy | 1 | 2009 | 6745 | 0.030 |
Why?
| | Microscopy, Confocal | 1 | 2017 | 327 | 0.030 |
Why?
| | Interviews as Topic | 1 | 2019 | 767 | 0.030 |
Why?
| | Drug Synergism | 1 | 2017 | 379 | 0.030 |
Why?
| | Pyrimidines | 1 | 2019 | 472 | 0.030 |
Why?
| | Pandemics | 1 | 2024 | 1619 | 0.030 |
Why?
| | Flow Cytometry | 1 | 2019 | 1185 | 0.030 |
Why?
| | Sequence Analysis, RNA | 1 | 2018 | 451 | 0.030 |
Why?
| | Predictive Value of Tests | 1 | 2020 | 2039 | 0.030 |
Why?
| | Sensitivity and Specificity | 1 | 2020 | 1950 | 0.030 |
Why?
| | Lumbar Vertebrae | 1 | 2016 | 245 | 0.030 |
Why?
| | Image Interpretation, Computer-Assisted | 1 | 2016 | 279 | 0.030 |
Why?
| | Illinois | 1 | 2013 | 43 | 0.030 |
Why?
| | Chicago | 1 | 2013 | 61 | 0.030 |
Why?
| | Quality Improvement | 1 | 2022 | 1161 | 0.030 |
Why?
| | Body Mass Index | 1 | 2022 | 2369 | 0.030 |
Why?
| | Necrosis | 1 | 2013 | 244 | 0.020 |
Why?
| | Qualitative Research | 1 | 2019 | 1361 | 0.020 |
Why?
| | History, 19th Century | 1 | 2011 | 61 | 0.020 |
Why?
| | SMARCB1 Protein | 1 | 2011 | 31 | 0.020 |
Why?
| | Germany | 1 | 2011 | 121 | 0.020 |
Why?
| | Case-Control Studies | 1 | 2019 | 3546 | 0.020 |
Why?
| | Incidence | 1 | 2018 | 2792 | 0.020 |
Why?
| | Clinical Competence | 1 | 2018 | 1093 | 0.020 |
Why?
| | Arthritis, Juvenile | 1 | 2011 | 56 | 0.020 |
Why?
| | Chromosomal Proteins, Non-Histone | 1 | 2011 | 130 | 0.020 |
Why?
| | Apoptosis | 1 | 2019 | 2557 | 0.020 |
Why?
| | Abducens Nerve Diseases | 1 | 2010 | 12 | 0.020 |
Why?
| | Practice Guidelines as Topic | 1 | 2018 | 1580 | 0.020 |
Why?
| | History, 20th Century | 1 | 2011 | 324 | 0.020 |
Why?
| | Brain Ischemia | 1 | 2014 | 341 | 0.020 |
Why?
| | Joint Dislocations | 1 | 2010 | 52 | 0.020 |
Why?
| | Range of Motion, Articular | 1 | 2011 | 392 | 0.020 |
Why?
| | Clothing | 1 | 2008 | 22 | 0.020 |
Why?
| | Obesity | 1 | 2022 | 2974 | 0.020 |
Why?
| | Statistics, Nonparametric | 1 | 2009 | 434 | 0.020 |
Why?
| | Bacterial Infections | 1 | 2009 | 251 | 0.020 |
Why?
| | Inflammation | 1 | 2018 | 2837 | 0.020 |
Why?
| | Cross-Sectional Studies | 1 | 2018 | 5427 | 0.020 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2013 | 2193 | 0.020 |
Why?
| | New York | 1 | 2003 | 133 | 0.010 |
Why?
| | Shock, Cardiogenic | 1 | 2003 | 63 | 0.010 |
Why?
| | Emergency Treatment | 1 | 2003 | 117 | 0.010 |
Why?
| | Risk Assessment | 1 | 2010 | 3439 | 0.010 |
Why?
| | Stroke Volume | 1 | 2003 | 619 | 0.010 |
Why?
| | Hospital Mortality | 1 | 2003 | 902 | 0.010 |
Why?
| | Heart Ventricles | 1 | 2003 | 792 | 0.010 |
Why?
| | Intensive Care Units | 1 | 2003 | 803 | 0.010 |
Why?
| | Time Factors | 1 | 2003 | 6817 | 0.010 |
Why?
| | Heart Failure | 1 | 2003 | 2222 | 0.010 |
Why?
|
|
Hankinson's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|